219 related articles for article (PubMed ID: 35768316)
21. Efficacy of Cabozantinib in Metastatic Papillary Renal Cell Carcinoma Following Ineffective Treatment With Initial Therapy of Nivolumab and Ipilimumab.
Tachibana H; Ishiyama Y; Yoshino M; Yamashita K; Toki D; Kondo T
In Vivo; 2021; 35(3):1743-1747. PubMed ID: 33910858
[TBL] [Abstract][Full Text] [Related]
22. Dissociated response among multiple metastatic lesions in the patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Negishi T; Nakagawa T; Nishiyama N; Kitamura H; Okajima E; Furubayashi N; Hori Y; Kuroiwa K; Son Y; Seki N; Tomoda T; Nakamura M
Jpn J Clin Oncol; 2022 Dec; 52(12):1430-1435. PubMed ID: 36093731
[TBL] [Abstract][Full Text] [Related]
23. Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
Pignot G; Thiery-Vuillemin A; Albigès L; Walz J; Lang H; Balssa L; Parier B; Geoffrois L; Bensalah K; Schlürmann F; Ladoire S; Bigot P; Borchiellini D; Cassuto O; Thibault C; Ingels A; Saldana V; Roubaud G; Bernhard JC; Gravis G; Barthélémy P
Eur Urol Oncol; 2022 Oct; 5(5):577-584. PubMed ID: 35853818
[TBL] [Abstract][Full Text] [Related]
24. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Gan CL; Dudani S; Wells JC; Donskov F; Pal SK; Dizman N; Rathi N; Beuselinck B; Yan F; Lalani AA; Hansen A; Szabados B; de Velasco G; Tran B; Lee JL; Vaishampayan UN; Bjarnason GA; Subasri M; Choueiri TK; Heng DYC
Cancer Med; 2021 Feb; 10(4):1212-1221. PubMed ID: 33463028
[TBL] [Abstract][Full Text] [Related]
25. Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors.
Santoni M; Massari F; Bracarda S; Grande E; Matrana MR; Rizzo M; De Giorgi U; Basso U; Aurilio G; Incorvaia L; Martignetti A; Molina-Cerrillo J; Mollica V; Rizzo A; Battelli N
Eur Urol Focus; 2022 Nov; 8(6):1696-1702. PubMed ID: 35193819
[TBL] [Abstract][Full Text] [Related]
26. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
[TBL] [Abstract][Full Text] [Related]
27. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
[TBL] [Abstract][Full Text] [Related]
28. Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.
Kido K; Hatakeyama S; Numakura K; Tanaka T; Oikawa M; Noro D; Hosogoe S; Narita S; Inoue T; Yoneyama T; Ito H; Nishimura S; Hashimoto Y; Kawaguchi T; Habuchi T; Ohyama C
Int J Clin Oncol; 2021 Jan; 26(1):154-162. PubMed ID: 33067647
[TBL] [Abstract][Full Text] [Related]
29. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.
Hammers HJ; Plimack ER; Infante JR; Rini BI; McDermott DF; Lewis LD; Voss MH; Sharma P; Pal SK; Razak ARA; Kollmannsberger C; Heng DYC; Spratlin J; McHenry MB; Amin A
J Clin Oncol; 2017 Dec; 35(34):3851-3858. PubMed ID: 28678668
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint inhibitors combined with tyrosine kinase inhibitors or immunotherapy for treatment-naïve metastatic clear-cell renal cell carcinoma-A network meta-analysis. Focus on cabozantinib combined with nivolumab.
Niewada M; Macioch T; Konarska M; Mela A; Goszczyński A; Przekopińska B; Rajkiewicz K; Wysocki P; Krzakowski M
Front Pharmacol; 2022; 13():1063178. PubMed ID: 36937206
[No Abstract] [Full Text] [Related]
31. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
32. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.
Studentova H; Rusarova N; Ondruskova A; Zemankova A; Student V; Skanderova D; Melichar B
Curr Oncol; 2022 Aug; 29(8):5475-5488. PubMed ID: 36005171
[TBL] [Abstract][Full Text] [Related]
33. First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.
Wan X; Zhang Y; Tan C; Zeng X; Peng L
JAMA Oncol; 2019 Apr; 5(4):491-496. PubMed ID: 30789633
[TBL] [Abstract][Full Text] [Related]
34. A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy.
Ornstein MC; Wood LS; Hobbs BP; Allman KD; Martin A; Bevan M; Gilligan TD; Garcia JA; Rini BI
J Immunother Cancer; 2019 May; 7(1):127. PubMed ID: 31097024
[TBL] [Abstract][Full Text] [Related]
35. Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors.
Nemoto Y; Ishihara H; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Kondo T; Takagi T
Jpn J Clin Oncol; 2023 Jun; 53(7):611-618. PubMed ID: 37002188
[TBL] [Abstract][Full Text] [Related]
36. Real-World Results of Cabozantinib Given as Alternative Schedule in Metastatic Renal Cell Carcinoma.
Bruchbacher A; Franke J; Alimohammadi A; Laukhtina E; Fajkovic H; Schmidinger M
Clin Genitourin Cancer; 2024 Apr; 22(2):98-108. PubMed ID: 37926597
[TBL] [Abstract][Full Text] [Related]
37. Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis.
Santoni M; Rizzo A; Mollica V; Rosellini M; Marchetti A; Fragomeno B; Battelli N; Massari F
Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):45-51. PubMed ID: 34058953
[TBL] [Abstract][Full Text] [Related]
38. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
[TBL] [Abstract][Full Text] [Related]
39. A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.
Reinhorn D; Sarfaty M; Leshno M; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Oncologist; 2019 Mar; 24(3):366-371. PubMed ID: 30710066
[TBL] [Abstract][Full Text] [Related]
40. Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma.
Bando Y; Furukawa J; Okamura Y; Hara T; Terakawa T; Nakano Y; Fujisawa M
Anticancer Res; 2022 Feb; 42(2):973-979. PubMed ID: 35093897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
